Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene

Journal of Rheumatology

Volumn 29, Issue 12, 2002, Pages 2492-2499

  Tanaka, Eiichi ^a   Taniguchi, Atsuo ^a   Urano, Wako ^a   Nakajima, Hiroshi ^a   Matsuda, Yuko ^a   Kitamura, Yutaka ^a   Saito, Masayuki ^a   Yamanaka, Hisashi ^a   Saito, Terunobu ^a   Kamatani, Naoyuki ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Adverse effects; Diplotype configuration; N acetyltransferase 2; Polymorphism; Rheumatoid arthritis; Sulfasalazine

Indexed keywords

ACYLTRANSFERASE; DNA; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; ARYLAMINE ACETYLTRANSFERASE; NAT2 PROTEIN, HUMAN;

ACETYLATOR PHENOTYPE; ADOLESCENT; ADULT; ARTHRITIS; ARTICLE; ASIAN; BONE MARROW SUPPRESSION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; ETHNIC GROUP; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM LIKELIHOOD METHOD; PHARMACOGENETICS; PRIORITY JOURNAL; RASH; RHEUMATOID ARTHRITIS; STOMATITIS; TREATMENT OUTCOME; ACETYLATION; ENZYMOLOGY; GENETICS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ACETYLATION; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARYLAMINE N-ACETYLTRANSFERASE; FEMALE; HAPLOTYPES; HUMANS; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SULFASALAZINE;

EID: 0036896055     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Hannonen P, Mottonen T, Hakola M, Oka M. Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 1993;36:1501-9.
2. Pinals RS, Kaplan SB, Lawson JG, Hepburn B. Sulfasalazine in rheumatoid arthritis. A double-blind, placebo-controlled trial. Arthritis Rheum 1986;29:1427-34.
3. McConkey B, Amos RS, Durham S, Forster PJ, Hubball S, Walsh L. Sulphasalazine in rheumatoid arthritis. BMJ 1980:280:442-4.
4. Neumann VC, Grindulis KA, Hubball S, McConkey B, Wright V. Comparison between penicillamine and sulphasalazine in rheumatoid arthritis. BMJ Clin Res Ed 1983;287:1099-102.
5. Pullar T, Hunter JA, Capell HA. Sulphasalazine in rheumatoid arthritis: A double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. BMJ Clin Res Ed 1983;287:1102-4.
6. Farr M, Tunn E, Crockson AP, Bacon PA. The long term effects of sulphasalazine in the treatment of rheumatoid arthritis and a comparative study with penicillamine. Clin Rheumatol 1984;3:473-81.
7. Bax DE, Amos RS. Sulphasalazine: A safe, effective agent for prolonged control of rheumatoid arthritis. A comparison with sodium aurothiomalate. Ann Rheum Dis 1985;44:194-8.
8. Amos RS, Pullar T, Bax DE, Situnayake D, Capell HA, McConkey B. Sulphasalazine for rheumatoid arthritis: Toxicity in 774 patients monitored for one to 11 years. BMJ Clin Res Ed 1986;293:420-3.
9. Donovan S, Hawley S, MacCarthy J, Scott DL. Tolerability of enteric-coated sulphasalazine in rheumatoid arthritis: Results of a co-operating clinics study. Br J Rheumatol 1990;29:201-4.
10. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum 1992;35:1117-25.
11. Blum M, Grant DM, McBride W. Heim M, Meyer UA. Human arylamine N-acetyltransferase genes: Isolation, chromosomal localization, and functional expression. DNA Cell Biol 1990;9:193-203.
12. Grant DM, Goodfellow GH, Sugamori K, Durette K. Pharmacogenetics of the human arylamine N-acetyltransferases. Pharmacology 2000;61:204-11.
13. Vatsis KP, Weber WW, Bell DA, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995;5:1-17.
14. Ilett KF, Kadlubar FF, Minchin RF. 1998 International Meeting on the Arylamine N-Acetyltransferases: Synopsis of the workshop on nomenclature, biochemistry, molecular biology, interspecies comparisons, and role in human disease risk. Drug Metab Dispos 1999;27:957-9.
15. Hein DW, Grant DM. Sim E. Update on consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenetics 2000;10:291-1
16. Bell DA, Taylor JA, Butler MA, et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993;14:1689-92.
17. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 1991;88:5237-41.
18. Deguchi T, Mashimo M, Suzuki T. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J Biol Chem 1990;265:12757-60.
19. Vatsis KP, Martell KJ, Weber WW. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc Natl Acad Sci USA 1991;88:6333-7.
20. Hickman D, Sim E. N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans. Biochem Pharmacol 1991;42:1007-14.
21. Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: Correlation with phenotypic activity. Am J Hum Genet 1995:57:581-92.
22. Pullar T, Hunter JA, Capell HA. Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis. Ann Rheum Dis 1985;44:831-7.
23. Kitas GD, Farr M, Waterhouse L, Bacon PA. Influence of acetylator status on sulphasalazine efficacy and toxicity in patients with rheumatoid arthritis. Scand J Rheumatol 1992;21:220-5.
24. Bax DE, Greaves MS, Amos RS. Sulphasalazine for rheumatoid arthritis: Relationship between dose, acetylator phenotype and response to treatment. Br J Rheumatol 1986:25:282-4.
25. Chalmers IM, Sitar DS, Hunter T. A one-year, open, prospective study of sulfasalazine in the treatment of rheumatoid arthritis: Adverse reactions and clinical response in relation to laboratory variables, drug and metabolite serum levels, and acetylator status. J Rheumatol 1990;17:764-70.
26. Laversuch CJ, Collins DA, Charles PJ, Bourke BE. Sulphasalazine-induced autoimmune abnormalities in patients with rheumatic disease. Br J Rheumatol 1995;34:435-9.
27. Lunde PK, Frislid K, Hansteen V. Disease and acetylator polymorphism. In: Gibaldi M, Prescott L, editors. Handbook of Clinical Pharmacokinetics. Sydney: Adis Health Science Press; 1983.
28. Harmer D, Evans DAP, Eze LC, Jolly M, Whibley EJ. The relationship between the acetylator and the sparteine hydroxylation polymorphisms. J Med Genet 1986:23:155-6.
29. Timbrell JA, Wright JM, Baillie TA. Monoacetylhydrazine as a metabolite of isoniazid in man. Clin Pharm Therap 1977;22:602-9.
30. Wadelius M, Stjernberg E, Wiholm BE, Rane A. Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis. Pharmacogenetics 2000;10:35-41.
31. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
32. Inatomi H, Katoh T, Kawamoto T, Matsumoto T. NAT2 gene polymorphism as a possible marker for susceptibility to bladder cancer in Japanese. Int J Urol 1999;6:446-54.
33. Kitamura Y, Moriguchi M, Kaneko H, et al. Determination of probability distribution of diplotype configuration (diplotype distribution) for each subject from genotypic data using the EM algorithm. Ann Hum Genet 2002;66:183-93.
34. Karch FE, Lasagna L. Adverse drug reactions. A critical review. JAMA 1975;234:1236-41.
35. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998;279:1200-5.
36. Deguchi T. Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver. J Biol Chem 1992;267:18140-7.
37. Lin HJ, Han CY, Lin BK, Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 1994;4:125-34.
38. Sekine A. Saito S, Iida A, et al. Identification of single-nucleotide polymorphisms of human N-acetyltransferase genes NAT1, NAT2, AANAT, ARDI and LICAM in the Japanese population. J Hum Genet 2001;46:314-9.
39. Okumura K, Kita T, Chikazawa S, Kodama F, Iwakawa S. Tanigawara Y. Genotyping of N-acetylation polymorphism and correlation with procainamide metabolism. Clin Pharmacol Ther 1997;61:509-17.
40. Gross M, Kruisselbrink T, Anderson K, et al. Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. Cancer Epidemiol Biomarkers Prev 1999;8:683-92.
41. Lin HJ, Han CY, Lin BK, Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: Application to metabolic epidemiology. Am J Hum Genet 1993;52:827-34.
42. Zhao B, Seow A, Lee EJ, Lee HP. Correlation between acetylation phenotype and genotype in Chinese women. Eur J Clin Pharmacol 2000;56:689-92.
43. Graf T, Broly F, Hoffmann F, Probst M, Meyer UA, Howald H. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers. Eur J Clin Pharmacol 1992;43:399-403.
44. Rothman N, Hayes RB, Bi W, et al. Correlation between N-acetyltransferase activity and NAT2 genotype in Chinese males. Pharmacogenetics 1993;3:250-5.
45. Ilett KF, Chiswell GM, Spargo RM, Platt E, Minchin RF. Acetylation phenotype and genotype in aboriginal leprosy patients from the north-west region of Western Australia. Pharmacogenetics 1993;3:264-9.
46. Abe M, Deguchi T, Suzuki T. The structure and characteristics of a fourth allele of polymorphic N-acetyltransferase gene found in the Japanese population. Biochem Biophys Res Commun 1993;191:811-6.
47. Hickman D, Risch A, Camilleri JP, Sim E. Genotyping human polymorphic arylamine N-acetyltransferase: Identification of new slow allotypic variants. Pharmacogenetics 1992;2:217-26.
48. Azad Khan AK, Howes DT, Piris J, Truelove SC. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut 1980;21:232-40.
49. Das KM, Eastwood MA, McManus JP, Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973;289:491-5.
50. Das KM, Eastwood MA. Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease. Clin Pharmacol Ther 1975;18:514-20.
51. Mikanagi K, Nishioka K, Sugawara S, et al. A prospective long term study of enteric-coated salazosulfapyridine in rheumatoid arthritis. Kiso to Rinsho 1991;25:1749-65.
52. Chiba M, Munakata A, Takahashi T, et al. Side Effects of Salicylazosulfapyridine in Inflammatory Bowel Disease. Annual Report of the Research Committee of Inflammatory Bowel Disease. Tokyo: The Ministry of Health and Welfare of Japan; 1994:105.
53. Nishioka K, Nobunaga M, Sakuma A. A double blind comparative study of 1 g/day, 2 g/day salazosulfapyridine and placebo in rheumatoid arthritis. Ryumachi 1991;31:327-45.
54. Sabbagh N, Delaporte E, Marez D, Lo-Guidice JM, Piette F, Broly F. NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus. Pharmacogenetics 1997;7:131-5.
55. Griesmacher A, Chiba P, Müller MM. Delayed hypersensitivity to 5-fluorouracil associated with reduced dihydropyrimidine dehydrogenase activity. In: Duley JA, Nethersell AB, editors. Purine and Pyrimidine Metabolism in Man. IX. New York: Plenum Press; 1998:147-50.
56. Rains CP, Noble S, Faulds D. Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 1995;50:137-56.